Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 1997

View Archived Issues

Gull Laboratories reports year-end and fourth-quarter results

Medtronic reports quarterly earnings up 20.8%

SmithKline Beecham reports strong growth for 1996, fueled by success of new products

T Cell Sciences reports 1996 fourth-quarter and year-end financial results

Unimed reports 1996 results: Earnings exceed published estimates

RCT discloses compounds for radiolabeling leukocytes/lymphocytes

Takeda describes antitumor agents

Antiarrhythmic agents reported by National Science Council

TK inhibitors disclosed by Pfizer

Cephalosporin antibiotics revealed by Microcide

Zeneca reports cell adhesion inhibitors

Novel class of immunosuppressants disclosed by Novartis

Comparative efficacy and tolerance of s.c. and i.m. Puregon

Dorzolamide and timolol alone and in combination for glaucoma

Sustained-release methylphenidate for HIV-associated cognitive impairment

Pramlintide delays gastric emptying in IDDM

Gamma-hydroxybutyrate associated with dependence liability

First launch for troglitazone

Celgene receives patent for selective cytokine-inhibitory drugs

Faulding receives approval for etodolac tablets

Teva's Tolmetin approved

Watson and Oclassen merge

Vyrex and SeqWright collaborate to develop CD-Tagging technology

ViroPharma receives milestone payment from Boehringer Ingelheim

Roche's Roferon-A receives EU approval

Hemagen's CMV diagnostic cleared for marketing

FDA advisory committee decision regarding Integrilin

ONYX expands ONYX-015 clinical trials

ViroPharma's antiviral candidate enters pediatric clinical trials

Advisory committee to review supplemental NDA for Maxipime

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...